435 related articles for article (PubMed ID: 18042703)
1. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.
Zang X; Thompson RH; Al-Ahmadie HA; Serio AM; Reuter VE; Eastham JA; Scardino PT; Sharma P; Allison JP
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19458-63. PubMed ID: 18042703
[TBL] [Abstract][Full Text] [Related]
2. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.
Zang X; Sullivan PS; Soslow RA; Waitz R; Reuter VE; Wilton A; Thaler HT; Arul M; Slovin SF; Wei J; Spriggs DR; Dupont J; Allison JP
Mod Pathol; 2010 Aug; 23(8):1104-12. PubMed ID: 20495537
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of B7-CD28 costimulation in urologic malignancies.
Thompson RH; Kwon ED; Allison JP
Immunotherapy; 2009 Jan; 1(1):129-39. PubMed ID: 20445772
[TBL] [Abstract][Full Text] [Related]
4. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases.
Chavin G; Sheinin Y; Crispen PL; Boorjian SA; Roth TJ; Rangel L; Blute ML; Sebo TJ; Tindall DJ; Kwon ED; Karnes RJ
Clin Cancer Res; 2009 Mar; 15(6):2174-80. PubMed ID: 19276267
[TBL] [Abstract][Full Text] [Related]
5. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
Roth TJ; Sheinin Y; Lohse CM; Kuntz SM; Frigola X; Inman BA; Krambeck AE; McKenney ME; Karnes RJ; Blute ML; Cheville JC; Sebo TJ; Kwon ED
Cancer Res; 2007 Aug; 67(16):7893-900. PubMed ID: 17686830
[TBL] [Abstract][Full Text] [Related]
6. High B7-H3 expression is linked to increased risk of prostate cancer progression.
Bonk S; Tasdelen P; Kluth M; Hube-Magg C; Makrypidi-Fraune G; Möller K; Höflmayer D; Dwertmann Rico S; Büscheck F; Minner S; Heinzer H; Graefen M; Hinsch A; Luebke AM; Dum D; Uhlig R; Schlomm T; Sauter G; Simon R; Weidemann SA
Pathol Int; 2020 Oct; 70(10):733-742. PubMed ID: 32776718
[TBL] [Abstract][Full Text] [Related]
7. Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis.
Katayama A; Takahara M; Kishibe K; Nagato T; Kunibe I; Katada A; Hayashi T; Harabuchi Y
Int J Oncol; 2011 May; 38(5):1219-26. PubMed ID: 21344157
[TBL] [Abstract][Full Text] [Related]
8. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer.
Loos M; Hedderich DM; Ottenhausen M; Giese NA; Laschinger M; Esposito I; Kleeff J; Friess H
BMC Cancer; 2009 Dec; 9():463. PubMed ID: 20035626
[TBL] [Abstract][Full Text] [Related]
9. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
10. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.
Benzon B; Zhao SG; Haffner MC; Takhar M; Erho N; Yousefi K; Hurley P; Bishop JL; Tosoian J; Ghabili K; Alshalalfa M; Glavaris S; Simons BW; Tran P; Davicioni E; Karnes RJ; Boudadi K; Antonarakis ES; Schaeffer EM; Drake CG; Feng F; Ross AE
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):28-35. PubMed ID: 27801901
[TBL] [Abstract][Full Text] [Related]
11. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
Kim GE; Kim NI; Park MH; Lee JS
Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
[TBL] [Abstract][Full Text] [Related]
12. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.
Boorjian SA; Sheinin Y; Crispen PL; Farmer SA; Lohse CM; Kuntz SM; Leibovich BC; Kwon ED; Frank I
Clin Cancer Res; 2008 Aug; 14(15):4800-8. PubMed ID: 18676751
[TBL] [Abstract][Full Text] [Related]
13. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction.
Leitner J; Klauser C; Pickl WF; Stöckl J; Majdic O; Bardet AF; Kreil DP; Dong C; Yamazaki T; Zlabinger G; Pfistershammer K; Steinberger P
Eur J Immunol; 2009 Jul; 39(7):1754-64. PubMed ID: 19544488
[TBL] [Abstract][Full Text] [Related]
14. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
Liu Y; Vlatkovic L; Sæter T; Servoll E; Waaler G; Nesland JM; Giercksky KE; Axcrona K
Int J Urol; 2012 Aug; 19(8):749-56. PubMed ID: 22487487
[TBL] [Abstract][Full Text] [Related]
15. Interactions of T cells with fibroblast-like synoviocytes: role of the B7 family costimulatory ligand B7-H3.
Tran CN; Thacker SG; Louie DM; Oliver J; White PT; Endres JL; Urquhart AG; Chung KC; Fox DA
J Immunol; 2008 Mar; 180(5):2989-98. PubMed ID: 18292521
[TBL] [Abstract][Full Text] [Related]
16. B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors.
Yuan Z; Gardiner JC; Maggi EC; Huang S; Adem A; Bagdasarov S; Li G; Lee S; Slegowski D; Exarchakis A; Howe JR; Lattime EC; Zang X; Libutti SK
Endocr Relat Cancer; 2021 Feb; 28(2):135-149. PubMed ID: 33410766
[TBL] [Abstract][Full Text] [Related]
17. Fine tuning the immune response through B7-H3 and B7-H4.
Yi KH; Chen L
Immunol Rev; 2009 May; 229(1):145-51. PubMed ID: 19426220
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
[TBL] [Abstract][Full Text] [Related]
19. B7-H3 over expression in prostate cancer promotes tumor cell progression.
Yuan H; Wei X; Zhang G; Li C; Zhang X; Hou J
J Urol; 2011 Sep; 186(3):1093-9. PubMed ID: 21784485
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma.
Sun J; Chen LJ; Zhang GB; Jiang JT; Zhu M; Tan Y; Wang HT; Lu BF; Zhang XG
Cancer Immunol Immunother; 2010 Aug; 59(8):1163-71. PubMed ID: 20333377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
